Brain activation patterns in medicated versus medication-naïve adults with attention-deficit hyperactivity disorder during fMRI tasks of motor inhibition and cognitive switching.


Journal

BMC medical imaging
ISSN: 1471-2342
Titre abrégé: BMC Med Imaging
Pays: England
ID NLM: 100968553

Informations de publication

Date de publication:
19 03 2021
Historique:
received: 26 10 2020
accepted: 04 03 2021
entrez: 20 3 2021
pubmed: 21 3 2021
medline: 27 1 2022
Statut: epublish

Résumé

Adult-attention-deficit-hyperactive-disorder (ADHD) is often unrecognized condition. FMRI examination along with neuropsychological testing might strengthen the diagnosis. We hypothesized that ADHD-adults with and without medication would show different fMRI pattern compared to healthy controls while testing tasks of motor inhibition and cognitive switching. 45 subjects in three age-matched groups: (1) controls, (2) ADHD-adults under medication (ADHD+) and (3) medication-naïve adults with ADHD (ADHD-) underwent fMRI and neuropsychological testing. Group analysis and population-based statistics were performed. DTVP-A, intellectual ability as well as attention capability, visual-perceptual and visual-motor abilities showed no significant differences between the groups. However, fMRI revealed statistically significant differences between the ADHD+, ADHD- and control groups on tasks of motor inhibition and cognitive switching on adults in bilateral fronto-striatal brain regions, inferior fronto-frontal, fronto-cingulate and fronto-parietal networks as well as in the parietal lobe (p < 0.05). fMRI offers the potential to differentiate between the ADHD+, ADHD- and control groups. FMRI possibly opens a new window for monitoring the therapeutic effect of ADHD medication. NCT02578342, registered at August 2015 to clinical trial registry ( https://ichgcp.net/clinical-trials-registry/NCT02578342 ).

Sections du résumé

BACKGROUND
Adult-attention-deficit-hyperactive-disorder (ADHD) is often unrecognized condition. FMRI examination along with neuropsychological testing might strengthen the diagnosis. We hypothesized that ADHD-adults with and without medication would show different fMRI pattern compared to healthy controls while testing tasks of motor inhibition and cognitive switching.
METHODS
45 subjects in three age-matched groups: (1) controls, (2) ADHD-adults under medication (ADHD+) and (3) medication-naïve adults with ADHD (ADHD-) underwent fMRI and neuropsychological testing. Group analysis and population-based statistics were performed.
RESULTS
DTVP-A, intellectual ability as well as attention capability, visual-perceptual and visual-motor abilities showed no significant differences between the groups. However, fMRI revealed statistically significant differences between the ADHD+, ADHD- and control groups on tasks of motor inhibition and cognitive switching on adults in bilateral fronto-striatal brain regions, inferior fronto-frontal, fronto-cingulate and fronto-parietal networks as well as in the parietal lobe (p < 0.05).
CONCLUSIONS
fMRI offers the potential to differentiate between the ADHD+, ADHD- and control groups. FMRI possibly opens a new window for monitoring the therapeutic effect of ADHD medication.
TRIAL REGISTRATION
NCT02578342, registered at August 2015 to clinical trial registry ( https://ichgcp.net/clinical-trials-registry/NCT02578342 ).

Identifiants

pubmed: 33740903
doi: 10.1186/s12880-021-00579-3
pii: 10.1186/s12880-021-00579-3
pmc: PMC7977301
doi:

Banques de données

ClinicalTrials.gov
['NCT02578342']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

53

Références

J Psychiatr Res. 2010 Jul;44(10):629-39
pubmed: 20060129
Neuroreport. 2001 Jul 3;12(9):2065-71
pubmed: 11435947
Eur Arch Psychiatry Clin Neurosci. 2006 Sep;256 Suppl 1:i42-6
pubmed: 16977551
Hum Brain Mapp. 2001 Mar;12(3):131-43
pubmed: 11170305
J Cogn Neurosci. 2005 Jan;17(1):124-36
pubmed: 15701244
J Abnorm Child Psychol. 2007 Apr;35(2):229-38
pubmed: 17351752
Cortex. 2013 Mar;49(3):837-49
pubmed: 22699024
Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8301-6
pubmed: 10393989
Ambul Pediatr. 2007 Jan-Feb;7(1 Suppl):73-81
pubmed: 17261486
JAMA Psychiatry. 2013 Feb;70(2):185-98
pubmed: 23247506
J Neurosci. 2007 Apr 4;27(14):3743-52
pubmed: 17409238
J Exp Psychol Hum Percept Perform. 1995 Jun;21(3):498-511
pubmed: 7790830
Neuroimage. 2002 Jun;16(2):449-53
pubmed: 12030830
Am J Psychiatry. 2006 Jun;163(6):1044-51
pubmed: 16741205
Cereb Cortex. 2001 Sep;11(9):825-36
pubmed: 11532888
Am J Addict. 2007;16 Suppl 1:24-32; quiz 33-4
pubmed: 17453604
Dev Med Child Neurol. 2019 Apr;61(4):399-405
pubmed: 30276811
Curr Psychiatry Rep. 2009 Oct;11(5):393-8
pubmed: 19785981
Neuropsychology. 2015 Nov;29(6):874-81
pubmed: 25938917
J Am Acad Child Adolesc Psychiatry. 2007 Dec;46(12):1633-41
pubmed: 18030085
Curr Opin Psychiatry. 2010 May;23(3):267-72
pubmed: 20308899
Hum Brain Mapp. 2006 Dec;27(12):973-93
pubmed: 16683265
J Exp Psychol Hum Percept Perform. 1984 Apr;10(2):276-91
pubmed: 6232345
Biol Psychiatry. 2011 Jun 15;69(12):e145-57
pubmed: 21550021
Transl Psychiatry. 2019 Nov 15;9(1):301
pubmed: 31732713
Hum Brain Mapp. 2004 Apr;21(4):247-56
pubmed: 15038006
Psychopharmacology (Berl). 2008 Aug;199(3):439-56
pubmed: 18542931
Dev Psychol. 1999 Jan;35(1):205-13
pubmed: 9923475
J Cogn Neurosci. 2011 Sep;23(9):2481-93
pubmed: 20849230
Hum Brain Mapp. 2001 Feb;12(2):100-9
pubmed: 11169874
Psychol Med. 2014 Mar;44(4):869-80
pubmed: 23663382
Am J Psychiatry. 2008 Jul;165(7):889-97
pubmed: 18413706
Neuroimage. 2001 Feb;13(2):250-61
pubmed: 11162266
Hum Brain Mapp. 2005 May;25(1):22-34
pubmed: 15846824
Neuroimage. 2005 Aug 15;27(2):323-40
pubmed: 16019232
Neuropsychologia. 2000;38(9):1280-91
pubmed: 10865104
Am J Psychiatry. 2012 Oct;169(10):1038-55
pubmed: 22983386
Hum Brain Mapp. 2007 Nov;28(11):1163-77
pubmed: 17538951
Neuroimage. 2003 Sep;20(1):351-8
pubmed: 14527595

Auteurs

Jatta Berberat (J)

Department of Neuroradiology, Kantonsspital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland. jatta.berberat@ksa.ch.
Department of Radiology and Medical Informatics, University of Geneva, 1202, Geneva, Switzerland. jatta.berberat@ksa.ch.

Ruth Huggenberger (R)

Praxisgemeinschaft Theaterplatz, 5400, Baden, Switzerland.

Margherita Montali (M)

Department of Neuroradiology, Kantonsspital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland.
Department of Ophthalmology, Kantonsspital Aarau, 5001, Aarau, Switzerland.

Philipp Gruber (P)

Department of Neuroradiology, Kantonsspital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland.

Achmed Pircher (A)

Department of Ophthalmology, Kantonsspital Aarau, 5001, Aarau, Switzerland.

Karl-Olof Lövblad (KO)

Department of Radiology and Medical Informatics, University of Geneva, 1202, Geneva, Switzerland.

Hanspeter E Killer (HE)

Department of Ophthalmology, Kantonsspital Aarau, 5001, Aarau, Switzerland.

Luca Remonda (L)

Department of Neuroradiology, Kantonsspital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland.
University of Bern, 3011, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH